{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [
    [
      "COVID-19 vaccines",
      "SARS-CoV-2",
      "effectiveness",
      "omicron"
    ]
  ],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "36298641",
  "DateCompleted": {
    "Year": "2022",
    "Month": "10",
    "Day": "31"
  },
  "DateRevised": {
    "Year": "2022",
    "Month": "11",
    "Day": "04"
  },
  "Article": {
    "ArticleDate": [
      {
        "Year": "2022",
        "Month": "09",
        "Day": "20"
      }
    ],
    "Language": [
      "eng"
    ],
    "ELocationID": [
      "2086",
      "10.3390/v14102086"
    ],
    "Journal": {
      "ISSN": "1999-4915",
      "JournalIssue": {
        "Volume": "14",
        "Issue": "10",
        "PubDate": {
          "Year": "2022",
          "Month": "Sep",
          "Day": "20"
        }
      },
      "Title": "Viruses",
      "ISOAbbreviation": "Viruses"
    },
    "ArticleTitle": "COVID-19 Vaccines against Omicron Variant: Real-World Data on Effectiveness.",
    "Abstract": {
      "AbstractText": [
        "The efficacy of vaccines against coronavirus disease 2019 (COVID-19) has now been well established in phase III clinical trials. However, clinical studies based on real-world data remain critical to assess vaccines effectiveness (VE), especially in specific populations and against variants of concern (VOC). This review presents the principles and methods of VE studies and the main available results on VE of COVID-19 vaccines at the time of Omicron circulation. References for this narrative review were identified through searches of PubMed database up to 13 September 2022. The results of phase III clinical trials have been globally confirmed by VE in real-life studies, including in the elderly. Emergence of VOC Omicron emphasized the importance of booster doses to maintain a high level of protection against severe forms. There are still numerous challenges regarding booster(s) and duration of immunity, particularly in specific subpopulations, and regarding the need for adapted vaccines."
      ]
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Assistance Publique H\u00f4pitaux de Paris, H\u00f4pital Cochin, Centre d'Investigation Clinique, 75014 Paris, France."
          },
          {
            "Identifier": [],
            "Affiliation": "Inserm, CIC 1417, F-CRIN, I-REIVAC, 75014 Paris, France."
          }
        ],
        "LastName": "Kherabi",
        "ForeName": "Yousra",
        "Initials": "Y"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Assistance Publique H\u00f4pitaux de Paris, H\u00f4pital Cochin, Centre d'Investigation Clinique, 75014 Paris, France."
          },
          {
            "Identifier": [],
            "Affiliation": "Inserm, CIC 1417, F-CRIN, I-REIVAC, 75014 Paris, France."
          },
          {
            "Identifier": [],
            "Affiliation": "Facult\u00e9 de Sant\u00e9, Universit\u00e9 Paris Cit\u00e9, 75006 Paris, France."
          }
        ],
        "LastName": "Launay",
        "ForeName": "Odile",
        "Initials": "O"
      },
      {
        "Identifier": [
          "0000-0002-5235-0868"
        ],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Assistance Publique H\u00f4pitaux de Paris, H\u00f4pital Cochin, Centre d'Investigation Clinique, 75014 Paris, France."
          },
          {
            "Identifier": [],
            "Affiliation": "Inserm, CIC 1417, F-CRIN, I-REIVAC, 75014 Paris, France."
          }
        ],
        "LastName": "Luong Nguyen",
        "ForeName": "Liem Binh",
        "Initials": "LB"
      }
    ],
    "PublicationTypeList": [
      "Journal Article",
      "Review"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "Switzerland",
    "MedlineTA": "Viruses",
    "NlmUniqueID": "101509722",
    "ISSNLinking": "1999-4915"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "COVID-19 Vaccines"
    }
  ],
  "SupplMeshList": [
    "SARS-CoV-2 variants"
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [],
      "DescriptorName": "Aged"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [
        "prevention & control"
      ],
      "DescriptorName": "COVID-19"
    },
    {
      "QualifierName": [],
      "DescriptorName": "COVID-19 Vaccines"
    },
    {
      "QualifierName": [
        "genetics"
      ],
      "DescriptorName": "SARS-CoV-2"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Clinical Trials, Phase III as Topic"
    }
  ],
  "CoiStatement": "The authors declare no conflict of interest."
}